Sugi Predict

Sugi Predict / Compounds / SCHEMBL797495

SCHEMBL797495

SCHEMBL797495

CC(C)(C)OC(=O)Nc1ccnc(Cl)c1F

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 1/20 0.56
▸ AAK1 Q2M2I8 5/20 0.47
▸ CYP17A1 P05093 3/20 0.42
▸ METAP1 P53582 1/20 0.42
▸ MAPKAPK2 P49137 1/20 0.37
▸ POLB P06746 2/20 0.37
▸ NAMPT P43490 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ SSTR4 P31391 1/20 0.37
▸ LMNA P02545 1/20 0.36
▸ TRPA1 O75762 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29418624 1.00 ATR (0.56) ATRAAK1CYP17A1METAP1MAPKAPK2
SCHEMBL16992920 0.85 ATR (0.46) ATRAAK1CYP17A1METAP1POLB
SCHEMBL30888170 0.85 ATR (0.59) ATRAAK1CYP17A1METAP1MAPKAPK2
SCHEMBL28584577 0.84 ATR (0.45) ATRAAK1CYP17A1METAP1POLB
SCHEMBL1866287 0.84 ATR (0.58) ATRAAK1CYP17A1METAP1MAPKAPK2
SCHEMBL4393718 0.84 ATR (0.58) ATRAAK1CYP17A1METAP1MAPKAPK2
SCHEMBL30413800 0.83 ATR (0.45) ATRAAK1CYP17A1METAP1POLB
SCHEMBL25693870 0.83 ATR (0.45) ATRAAK1CYP17A1METAP1POLB
SCHEMBL16992929 0.83 ATR (0.44) ATRAAK1CYP17A1METAP1POLB
SCHEMBL38662365 0.83 ATR (0.47) ATRAAK1CYP17A1METAP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
US-20260109716-A1 CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO ARVINAS OPERATIONS, INC. (US) 2026-04-23 — — US disclosed
EP-4655073-A2 CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO Arvinas Operations, Inc. (US) 2025-12-03 — — EP disclosed
US-12448399-B2 Cereblon-based KRAS degrading PROTACs and uses related thereto ARVINAS OPERATIONS, INC. (US) 2025-10-21 — — US disclosed
US-20250270206-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS NNSA 2025-08-28 — — US disclosed
US-20250084079-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS LEIDOS BIOMEDICAL RESEARCH, INC. 2025-03-13 — — US disclosed
WO-2025024732-A1 COMPOUNDS USEFUL IN THE TREATMENT OF KRAS MEDIATED DISORDERS ARVINAS OPERATIONS, INC. (US) 2025-01-30 — — WO disclosed
CN-118725012-A Compound capable of inducing KRAS protein degradation and preparation method and application thereof 中国科学院上海药物研究所 2024-10-01 — — CN disclosed
CN-118696036-A PARP1 inhibitors 突触活化疗法股份有限公司 2024-09-24 — — CN disclosed
US-20240309020-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2024-09-19 — — US disclosed
US-8697708-B2 Azabenzothiazole compounds, compositions and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-04-15 — — US disclosed
EP-2616072-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F.HOFFMANN-LA ROCHE AG (CH) 2013-07-24 — — EP disclosed
WO-2013099041-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF 富士フイルム株式会社 (JP) 2013-07-04 — — WO disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 — — US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 — — US disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 — — EP disclosed
CN-102958918-A Novel nicotinamide derivatives or salts thereof FUJIFILM CORP 2013-03-06 — — CN disclosed
US-20120202788-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 — — US disclosed
WO-2012035039-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-03-22 — — WO disclosed
WO-2012002577-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF 富士フイルム株式会社 (JP) 2012-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12448399-B2 Cereblon-based KRAS degrading PROTACs and uses related thereto CRBN, KRAS, WEE1 ATR 1283/4885AAK1 2927/4885CYP17A1 2459/4885
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK ATR 1155/4885AAK1 1635/4885CYP17A1 3923/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS ATR 2461/4885AAK1 1578/4885CYP17A1 2467/4885
US-20250084079-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS KRAS, NRAS, HRAS ATR 1124/4885AAK1 2217/4885CYP17A1 2525/4885
US-20250270206-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS KRAS, NRAS, HRAS ATR 916/4885AAK1 2088/4885CYP17A1 3107/4885
US-20120202788-A1 AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F12, CHRM1, NPY1R ATR 2146/4885AAK1 4210/4885CYP17A1 1172/4885
US-20260109716-A1 CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO KRAS, CRBN, HRAS ATR 1438/4885AAK1 2663/4885CYP17A1 3674/4885
US-20240309020-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS ATR 1869/4885AAK1 2810/4885CYP17A1 2904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.